iShares US Pharma

Lilly Asia Ventures Participates in Accro Bioscience's $50 Million Series C Financing

Investment firm Gambit Capital Management makes a new $26.54 million investment in Eli Lilly

Japan Approves Eli Lilly's Zepbound for Obstructive Sleep Apnea

Eli Lilly Scales Up AI-Driven Drug R&D and Production with Dell Solutions

Merck Plans to Issue $6 Billion in Bonds to Fund Terns Pharmaceutical Acquisition

FactSet Survey: Analysts Cut ZTS Median Price Target to $117

FDA Accepts Viatris Meloxicam NDA, PDUFA Date Set for Dec 2026

Harbour BioMed releases positive preclinical obesity data on its potential rival drug, LET003

Elanco Launches New Anti-IL-31 Monoclonal Antibody Befrena for Canine Allergic Dermatitis

Merck Announces Experimental Endometrial Cancer Drug Meets Primary Endpoint in Late-Stage Trial

Novo Nordisk plans to launch Wegovy oral weight-loss drug outside the US, intensifying competition with Eli Lilly

Eli Lilly announces its RET kinase inhibitor selpercatinib has entered a Phase III clinical trial for the first-line treatment of RET fusion-positive lung cancer

Eli Lilly and other Fortune 500 pharmaceutical giants establish a presence in Beijing International Pharmaceutical Innovation Park

Report claims Trump purchased Eli Lilly stock during period of favorable government policies

Investment firm GLOBALT increases its stake in Eli Lilly and Company

Multiple analyst firms update ratings and earnings forecasts for Eli Lilly

Eli Lilly's Q1 2026 revenue soars 56%, topping global pharmaceutical sales charts

Nanobiotix Reports 85.7% Response Rate for JNJ-1900 in Lung Cancer Trial Phase II

Eli Lilly and Company to Participate in EASD Industry Symposium

Institutional Investors Show Mixed Changes in Eli Lilly Holdings

AMPLITECH GROUP INC. COM USD0.001 (S/R 18/07/2026)

AMPLITECH GROUP INC. USD0.001 S/R 20/11/26 SER B

Wellgistics Health

Huachen AI Parking Management Tech

GeoVax Labs

Sunshine Biopharma

AIM ImmunoTech

Virax Biolabs

NextNRG

GCT Semiconductor

Pinned News

置顶新闻

CICC Cuts ZAI LAB  TP to HKD20.2; 1Q Results In Line

ZLAB

LABU

CICC has reduced ZAI LAB's target price to HKD20.2 following a report indicating a 6% YoY revenue decline to USD99.6 million and a net loss of USD51 million in 1Q. The results met expectations. The broker highlighted ongoing Phase III trials and multiple candidates entering clinical stages. CICC adjusted its 2026 and 2027 earnings forecasts, predicting larger net losses, while maintaining an Outperform rating.

- CICC reported that ZAI LAB (09688.HK) had a revenue of USD 99.6 million in Q1, a 6% YoY decline, with a net loss of USD 51 million, aligning with expectations.  
- The company is advancing its pipeline, with Zoci in Phase III trials and ZL1503 and ZL6201 in earlier clinical stages, while recent earnings forecasts have been downgraded due to competitive pricing pressures.  
- CICC lowered the 2026 net loss projection for ZAI LAB from USD 226 million to USD 248 million and maintained an Outperform rating, reducing the target price by 8%.

AASTOCKS News

Zai Lab

Invesco Biotechnology & Genome ETF

SPDR S&P Biotech

iShares Biotechnology ETF

Direxion S&P Biotech Bull 3X

VG Health

ZAI LAB

CICC

BAYN

BAYRY

ARKG

SBIO

Bayer AG announced that the U.S. FDA has granted Priority Review for Asundexian, an oral Factor Xla inhibitor aimed at preventing secondary strokes. This follows positive results from the Phase 3 OCEANIC-STROKE trial. The Priority Review designation highlights the urgency for new secondary stroke prevention methods. Stroke is a leading cause of death in the U.S., with 795,000 cases annually. Bayer's stock closed at $11.02, up 1.10%.

nasdaq

Bayer AG

Bayer

Health Care Select Sector SPDR

VanEck Biotech ETF

Ark Genomic Revolution ETF

iShares Global Healthcare

First Trust NYSE Arca Biotech Index Fd

ALPS Medical Breakthrough

Nasdaq

Bayer Aktiengesellschaft

Bayer Granted Priority Review For Asundexian In Secondary Stroke Prevention

Barclays analyst Charles Pitman maintained a Buy rating on Bayer with a price target of €50.00. Pitman has a 4-star rating with an average return of 11.4%. UBS also rated Bayer as a Buy, while Deutsche Bank issued a Hold rating on the same day.

Tip Ranks

Proshares Ultra Nasdaq Biotech

Barclays

UBS Group AG

Deutsche Bank AG

Deutsche Bank AG Subscription Rights

Deutsche Postbank AG

Barclays Remains a Buy on Bayer (0P6S)

SBFMW

SBFM

Sunshine Biopharma Inc. has priced a $6 million public offering, consisting of 12 million common units at $0.50 each, sending shares up 79.51% to $0.51. The offering includes Series C warrants exercisable at $0.50 for five years. Proceeds will support corporate purposes and working capital. The company markets 60 generic drugs in Canada and plans to launch 12 more in 2026, while advancing proprietary programs targeting oncology and SARS-related coronaviruses.

SUNSHINE BIOPHARMA INC C/WTS (TO PUR COM)

Sunshine Biopharma Prices $6M Offering; Closing May 19

NBIX

SLNO

Neurocrine Biosciences, Inc. presented new findings on INGREZZA's impact on mild tardive dyskinesia at the APA 2026 meeting, showing significant improvements in patient functional status. The company also completed its acquisition of Soleno Therapeutics for $2.9 billion, enhancing its rare disease portfolio. INGREZZA is FDA-approved for treating tardive dyskinesia and chorea associated with Huntington's disease. Neurocrine's stock closed at $157.21, down 0.76%, but rose 0.50% in after-hours trading.

Neurocrine Biosciences

Soleno Therapeutics

Goldman Sachs

GS Hldg R

Neurocrine Unveils New INGREZZA Findings In Mild Tardive Dyskinesia At APA 2026; Closes Soleno Deal

BMRN

IBBQ

BioMarin’s BMN 401 raised plasma PPi over 52 weeks in children but showed no meaningful rickets or growth improvement. Shares fell about 3% to ~$50.10 after the announcement.12HC Wainwright & Co. reiterated a Neutral rating on BioMarin Pharmaceutical Inc. (BMRN) and lowered its price target for the stock from $55.00 to $50.00 per share.3

TradingView

BioMarin Pharma

Invesco Nasdaq Biotechnology ETF

Key facts: BMN 401 Raises Plasma PPi; No Rickets/Growth Benefit; PT $50

ATRA

Rosen Law Firm is reminding investors who purchased Atara Biotherapeutics, Inc. (NASDAQ: ATRA) securities between May 20, 2024, and January 9, 2026, of the May 22, 2026, lead plaintiff deadline for a securities fraud lawsuit. Investors may be entitled to compensation without upfront fees. The lawsuit alleges that Atara made misleading statements regarding manufacturing issues and regulatory prospects, leading to investor damages when the truth emerged.

prnewswire

Atara Biotherap

21:12 ETATRA Investors Have Opportunity to Lead Atara Biotherapeutics, Inc. Securities Fraud Lawsuit

LLYX

The company is riding an incredible tailwind.

Eli Lilly

Defiance Daily Target 2X Long LLY ETF

Direxion Daily LLY Bull 2X Shares

Eli Lilly stock: Next stop $2,000?

NTHI

NeOnc Technologies Holdings, Inc. reported progress in its glioma programs, completing a Phase 1 study of NEO212 and enrolling in a Phase 2a trial of NEO100. The company improved its financial position with a $10 million PIPE financing and reduced its quarterly net loss to $8.8 million. Analysts rate NTHI stock as a Buy with a $20.00 target, though concerns about financial performance persist. NeOnc focuses on CNS cancers, developing drugs under FDA Fast-Track status.

Neonc Tech

NeOnc Advances Glioma Programs and Strengthens Financial Position

REGN

Levi & Korsinsky is investigating Regeneron Pharmaceuticals (REGN) following significant stock losses after the failure of its Phase 3 melanoma trial of fianlimab + Libtayo. The stock dropped over 10% after the trial did not meet its primary endpoint. Shareholders who suffered losses are encouraged to contact the firm for potential legal recourse.

Regeneron Pharma

Direxion S&P Biotech Bear 3X

18:24 ETRegeneron Pharmaceuticals Investigation Initiated: Levi & Korsinsky Investigates the Officers and Directors of Regeneron Pharmaceuticals (REGN)

Health-care companies saw gains as traders shifted focus to underperforming sectors. However, Regeneron Pharmaceuticals experienced a significant drop in shares following a failed late-stage study of its fianlimab drug for melanoma. Additionally, an American contracted Ebola in the Democratic Republic of Congo amid an ongoing outbreak.

MorningStar

Health Care Up on Rotation Into Lagging Sectors — Health Care Roundup

Novo Nordisk AS

Direxion Daily LLY Bear 1X Shares

Novo Nordisk's U.S. stock pre-market fell 11%, while Eli Lilly rose over 4% in pre-market trading. Novo Nordisk's CagriSema performed worse than Eli Lilly's Zepbound in trials

Wallstreetcn

iShares US Pharma(IHE.US)

CICC Cuts ZAI LAB TP to HKD20.2; 1Q Results In Line

Bayer Granted Priority Review For Asundexian In Secondary Stroke Prevention

Barclays Remains a Buy on Bayer (0P6S)

Sunshine Biopharma Prices $6M Offering; Closing May 19

Neurocrine Unveils New INGREZZA Findings In Mild Tardive Dyskinesia At APA 2026; Closes Soleno Deal